HPV-DNA im Samen von Männern im Rahmen der assistierten Reproduktion

2010 ◽  
Vol 70 (03) ◽  
Author(s):  
O Reich ◽  
H Auner ◽  
P Puerstner
Keyword(s):  
Hpv Dna

Entscheidungsanalytische Evaluation der Langzeiteffektivität und Kosteneffektivität der HPV-DNA-Diagnostik als Primärscreeningverfahren in der Zervixkarzinomfrüherkennung in Deutschland

2010 ◽  
Vol 72 (08/09) ◽  
Author(s):  
G Sroczynski ◽  
P Schnell-Inderst ◽  
N Mühlberger ◽  
K Lang ◽  
P Aidelsburger ◽  
...  
Keyword(s):  
Hpv Dna

HPV-DNA-Integration in Oropharynxkarzinomen

2004 ◽  
Vol 83 (02) ◽  
Author(s):  
JP Klussmann ◽  
S Dinh ◽  
C Wittekindt ◽  
L Turek ◽  
E Smith ◽  
...  
Keyword(s):  
Dna Integration ◽  
Hpv Dna

HPV-DNA Nachweis als prognostischer Marker bei Oropharynxkarzinomen

2004 ◽  
Vol 83 (02) ◽  
Author(s):  
S Dinh ◽  
JP Klussmann ◽  
O Guntinas-Lichius ◽  
S Weißenborn ◽  
H Pfister ◽  
...  
Keyword(s):  
Hpv Dna ◽  
Prognostischer Marker

Hypothetical Genes Are Frequent Targets of HPV DNA Integration in Cervical Carcinomas

2005 ◽  
Vol 127 (04) ◽  
Author(s):  
T Koch ◽  
I Kraus ◽  
C Ziegert ◽  
A Schneider ◽  
M Dürst
Keyword(s):  
Dna Integration ◽  
Hpv Dna ◽  
Cervical Carcinomas ◽  
Hypothetical Genes

Comparative Evaluation of the HPV28 Detection and HPV DNA Chip Test for Detecting and Genotyping Human Papillomaviruses

2013 ◽  
Vol 3 (4) ◽  
pp. 234 ◽  
Author(s):  
Eunsim Shin ◽  
Heojin Bae ◽  
Wan-Keun Song ◽  
Sun-Kyung Jung ◽  
Yoo-Sung Hwang
Keyword(s):  
Comparative Evaluation ◽  
Human Papillomaviruses ◽  
Dna Chip ◽  
Hpv Dna

scholarly journals Development and validation of a multiplex qPCR assay for detection and relative quantification of HPV16 and HPV18 E6 and E7 oncogenes

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Alexia Bordigoni ◽  
Anne Motte ◽  
Hervé Tissot-Dupont ◽  
Philippe Colson ◽  
Christelle Desnues
Keyword(s):  
Limit Of Detection ◽  
Quantitative Polymerase Chain Reaction ◽  
Human Papillomaviruses ◽  
Molecular Techniques ◽  
Clinical Samples ◽  
Gene Encoding ◽  
Hpv Dna ◽  
E6 And E7 ◽  
High Risk Hpv ◽  
Development And Validation

AbstractHuman papillomaviruses (HPV) play a key role in promoting human anogenital cancers. Current high-risk HPV screening or diagnosis tests involve cytological or molecular techniques mostly based on qualitative HPV DNA detection. Here, we describe the development of a rapid quantitative polymerase chain reaction (qPCR) detection test of HPV16 and HPV18 oncogenes (E6 and E7) normalized on human gene encoding GAPDH. Optimized qPCR parameters were defined, and analytical specificities were validated. The limit of detection was 101 for all genes tested. Assay performances were evaluated on clinical samples (n = 96). Concordance between the Xpert HPV assay and the triplex assay developed here was 93.44% for HPV16 and 73.58% for HPV18. HPV co-infections were detected in 15 samples. The systems developed in the present study can be used in complement to traditional HPV tests for specifically validating the presence of HPV16 and/or HPV18. It can also be used for the follow-up of patients with confirmed infection and at risk of developing lesions, through the quantification of E6 and E7 oncogene expression (mRNA) normalized on the GAPDH expression levels.

scholarly journals Association of serum 25-hydroxyvitamin D with prevalence, incidence, and clearance of vaginal HPV infection in young women

2020 ◽  
Author(s):  
Mariam El-Zein ◽  
Farzin Khosrow-Khavar ◽  
Ann N Burchell ◽  
Pierre-Paul Tellier ◽  
Shaun Eintracht ◽  
...  
Keyword(s):  
Vitamin D ◽  
Proportional Hazards ◽  
Hpv Infection ◽  
Cox Proportional Hazards ◽  
Baseline Serum ◽  
Hpv Dna ◽  
Hydroxyvitamin D ◽  
Hpv Prevalence ◽  
Vitamin D Levels ◽  
25 Hydroxyvitamin D

Abstract Background We assessed the association between serum 25-hydroxyvitamin D levels and genital human papillomavirus (HPV) prevalence, incidence, and clearance among female participants of the HITCH cohort study. Methods We genotyped HPV DNA in vaginal samples and quantified baseline serum 25-hydroxyvitamin D levels using Roche’s Linear Array and Total vitamin D assay, respectively. We used logistic and Cox proportional hazards models to respectively estimate adjusted odds ratios (OR) and hazards ratios (HR) with 95% confidence intervals (CI). Results There was no association between vitamin D levels (every 10ng/mL increase) at baseline and HPV prevalence (OR=0.88, CI:0.73-1.03) or incidence (HR=0.88, CI:0.73-1.06), but we observed a modest negative association with HPV clearance (HR=0.76, CI:0.60-0.96). Vitamin D levels <30ng/mL, compared to ≥30ng/mL, were not associated with HPV prevalence (OR=0.98, CI:0.57-1.69) or incidence (HR=0.87, CI:0.50-1.43), but were associated with a marginally significant increased clearance (OR=2.14, CI:0.99-4.64). We observed consistent results with restricted cubic spline modelling of vitamin D levels and clinically defined categories. HPV type-specific analyses accounting for multiple HPV infections per participant showed no association between vitamin D levels and all study outcomes. Conclusion This study provided no evidence of an association between low vitamin D levels and increased HPV prevalence, acquisition, or clearance.

scholarly journals Risk Factors for NON-HPV16/18 Cervical Infections and Associated Lesions Among HPV-DNA-Negative Women Vaccinated Against HPV16/18 in the Costa Rica Vaccine Trial (CVT)

2020 ◽  
Author(s):  
Mónica S Sierra ◽  
Sabrina H Tsang ◽  
Shangying Hu ◽  
Carolina Porras ◽  
Rolando Herrero ◽  
...  
Keyword(s):  
Sexual Behavior ◽  
Vaccine Trial ◽  
Smoking Behavior ◽  
Related Factors ◽  
Hpv Dna ◽  
Associated Lesions ◽  
Risk Of Progression ◽  
Specific Incident ◽  
Injectable Contraceptives ◽  
Baseline Bmi

Abstract Background Factors that lead human papillomavirus (HPV) infections to persist and progress to cancer are not fully understood, especially among vaccinated women. We evaluated co-factors for acquisition, persistence and progression of non-HPV16/18 infections in a cohort of HPV-vaccinated women. Methods We analyzed 2,153 18-25-year-old women randomized to the HPV-vaccine arm of CVT. Women were HPV-DNA-negative for all types at baseline and followed for ~11 years. Acquisition was a type-specific cervical infection not present/detected at the previously scheduled visit. Persistence was a type-specific incident infection that persisted for ≥1-year with no intervening negatives. Progression of persistent incident infections to CIN2+ was based on histological findings by expert pathologists. GEE methods were used to account for correlated observations. Time-dependent factors evaluated were age, sexual behavior, marital status, hormonal-related factors, number of full-term pregnancies (FTP), smoking behavior, and baseline-BMI. Results 1,777 incident oncogenic non-HPV16/18 infections were detected in 12,292 visits (average 0.14 infections per visit). Age and sexual behavior-related variables were associated with oncogenic non-HPV16/18 acquisition. 26% of incident infections persisted for ≥1-year. None of the factors evaluated were statistically associated with persistence of oncogenic non-HPV16/18 infections. Risk of progression to CIN2+ increased with increasing age (p-trend=0.001), injectable contraceptives use [relative risk 2.61 (95%CI 1.19–5.73) ever vs. never] and increasing FTP (p-trend=0.034). Conclusion In a cohort of HPV16/18-vaccinated women, age and sexual behavior variables are associated with acquisition of oncogenic non-HPV16/18 infections, no notable factors are associated with persistence of acquired oncogenic non-HPV16/18 infections, and age, parity and hormonally-related exposures are associated with progression to CIN2+.

Sign in / Sign up

Export Citation Format

Share Document